genetics; epilepsy; neurodevelopmental disorders; ion channel; bioinformatics
Abstract :
[en] Clinically identified genetic variants in ion channels can be benign or cause disease by increasing or decreasing the protein function. Consequently, therapeutic decision-making is challenging without molecular testing of each variant. Our biophysical knowledge of ion channel structures and function is just emerging, and it is currently not well understood which amino acid residues cause disease when mutated.We sought to systematically identify biological properties associated with variant pathogenicity across all major voltage and ligand-gated ion channel families. We collected and curated 3,049 pathogenic variants from hundreds of neurodevelopmental and other disorders and 12,546 population variants for 30 ion channel or channel subunits for which a high-quality protein structure was available. Using a wide range of bioinformatics approaches, we computed 163 structural features and tested them for pathogenic variant enrichment. We developed a novel 3D spatial distance scoring approach that enables comparisons of pathogenic and population variant distribution across protein structures.We discovered and independently replicated that several pore residue properties and proximity to the pore axis were most significantly enriched for pathogenic variants compared to population variants. Using our 3D scoring approach, we showed that the strongest pathogenic variant enrichment was observed for pore-lining residues and alpha-helix residues within 5Å distance from the pore axis center and not involved in gating. Within the subset of residues located at the pore, the hydrophobicity of the pore was the feature most strongly associated with variant pathogenicity. We also found an association between the identified properties and both clinical phenotypes and functional in vitro assays for voltage-gated sodium channels (SCN1A, SCN2A, SCN8A) and N-methyl-D-aspartate (NMDA) receptor (GRIN1, GRIN2A, GRIN2B) encoding genes. In an independent expert-curated dataset of 1,422 neurodevelopmental disorder pathogenic patient variants and 679 electrophysiological experiments, we show that pore axis distance is associated with seizure age of onset and cognitive performance as well as differential gain vs. loss-of-channel function.In summary, we identified biological properties associated with ion-channel malfunction and show that these are correlated with in vitro functional read-outs and clinical phenotypes in patients with neurodevelopmental disorders. Our results suggest that clinical decision support algorithms that predict variant pathogenicity and function are feasible in the future.
Research center :
- Luxembourg Centre for Systems Biomedicine (LCSB): Bioinformatics Core (R. Schneider Group)
Disciplines :
Neurology Genetics & genetic processes
Author, co-author :
Brünger, Tobias
Pérez-Palma, Eduardo
Montanucci, Ludovica
Nothnagel, Michael
Møller, Rikke S.
Schorge, Stephanie
Zuberi, Sameer
Symonds, Joseph
Lemke, Johannes R.
Brunklaus, Andreas
Traynelis, Stephen F.
May, Patrick ; University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) > Bioinformatics Core
Kim JB. Channelopathies. Korean J Pediatr. 2014;57:1-18.
Bajaj S, Ong ST, Chandy KG. Contributions of natural products to ion channel pharmacology. Nat Prod Rep. 2020;37:703-16.
Nayak S, Batalov S, Jegla T, Zmasek C. Evolution of the human ion channel set. Comb Chem High Throughput Screen. 2009;12: 2-23.
Addis L, Virdee JK, Vidler LR, Collier DA, Pal DK, Ursu D. Epilepsy-associated GRIN2A mutations reduce NMDA receptor trafficking and agonist potency "Molecular profiling and functional rescue. Sci Rep. 2017;7:66.
Rivaud MR, Delmar M, Remme CA. Heritable arrhythmia syndromes associated with abnormal cardiac sodium channel function: Ionic and non-ionic mechanisms. Cardiovasc Res. 2020;116:1557-70.
Hansen KB, Wollmuth LP, Bowie D, et al. Structure, function, and pharmacology of glutamate receptor ion channels. Pharmacol Rev. 2021;73:298-487.
Allen NM, Weckhuysen S, Gorman K, King MD, Lerche H. Genetic potassium channel-associated epilepsies: Clinical review of the Kv family. Eur J Paediatr Neurol. 2019;24:105-16.
Chuang SH, Reddy DS. Genetic and molecular regulation of extrasynaptic GABA-A receptors in the brain: Therapeutic insights for epilepsy. J Pharmacol Exp Ther. 2018;364:180-97.
Catterall WA. Sodium channel mutations and epilepsy. In: Noebels JL, Avoli M, Rogawski MA, Olsen RW, Delgado-Escueta AV, eds. Jasper (tm)s basic mechanisms of the epilepsies. 4th edn. National Center for Biotechnology Information (US); 2012.
Klassen T, Davis C, Goldman A, et al. Exome sequencing of ion channel genes reveals complex profiles confounding personal risk assessment in epilepsy. Cell. 2011;145:1036-48.
Baez-Nieto D, Allen A, Akers-Campbell S, et al. Analysing an allelic series of rare missense variants of CACNA1I in a Swedish schizophrenia cohort. Brain. 2022;145:1839-53.
Silk M, Pires DEV, Rodrigues CHM, et al. MTR3D: Identifying regions within protein tertiary structures under purifying selection. Nucleic Acids Res. 2021;49:W438-45.
Kamburov A, Lawrence MS, Polak P, et al. Comprehensive assessment of cancer missense mutation clustering in protein structures. Proc Natl Acad Sci USA. 2015;112:E5486-95.
Sivley RM, Dou X, Meiler J, Bush WS, Capra JA. Comprehensive analysis of constraint on the spatial distribution of missense variants in human protein structures. Am J Hum Genet. 2018; 102:415-26.
Reynolds C, King MD, Gorman KM The phenotypic spectrum of SCN2A-related epilepsy. Eur J Paediatr Neurol. 2020;24:117-22.
Goto A, Ishii A, Shibata M, Ihara Y, Cooper EC, Hirose S. Characteristics of KCNQ2 variants causing either benign neonatal epilepsy or developmental and epileptic encephalopathy. Epilepsia. 2019;60:1870-80.
Johannesen KM, Liu Y, Koko M, et al. Genotype-phenotype correlations in SCN8A-related disorders reveal prognostic and therapeutic implications. Brain. 2022;145:2991-3009.
Strehlow V, Heyne HO, Vlaskamp DRM, et al. GRIN2A-related disorders: Genotype and functional consequence predict phenotype. Brain. 2019;142:80-92.
Kelly M, Park M, Mihalek I, et al. Spectrum of neurodevelopmental disease associated with the GNAO1 guanosine triphosphatebinding region. Epilepsia. 2019;60:406-18.
Wu RH, Tang WT, Qiu KY, et al. Identification of novel CSNK2A1 variants and the genotype-phenotype relationship in patients with Okur-Chung neurodevelopmental syndrome: A case report and systematic literature review. J Int Med Res. 2021;49: 03000605211017063.
Brunklaus A, Du J, Steckler F, et al. Biological concepts in human sodium channel epilepsies and their relevance in clinical practice. Epilepsia. 2020;61:387-99.
Brunklaus A, Feng T, Br 1/4nger T, et al. Gene variant effects across sodium channelopathies predict function and guide precision therapy. Brain. Published online 17 January 2022. doi:10.1093/brain/awac006.
Armstrong JF, Faccenda E, Harding SD, et al. The IUPHAR/BPS guide to pharmacology in 2020: Extending immunopharmacology content and introducing the IUPHAR/MMV guide to malaria pharmacology. Nucleic Acids Res. 2020;48:D1006-21.
Landrum MJ, Lee JM, Benson M, et al. Clinvar: Improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 2018;46:D1062-7.
Berman HM, Westbrook J, Feng Z, et al. The Protein Data Bank. Nucleic Acids Res. 2000;28:235-42.
Yates B, Gray KA, Jones TEM, Bruford EA. Updates to HCOP: The HGNC comparison of orthology predictions tool. Briefings in Bioinformatics. 2021;22:bbab155.
Consortium TU. UniProt: A worldwide hub of protein knowledge. Nucleic Acids Res. 2019;47:D506-15.
Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581:434-43.
Stenson PD, Ball EV, Mort M, et al. Human Gene Mutation Database (HGMD): 2003 update. Hum Mutat. 2003;21:577-81.
SCN Portal. Accessed 1 December 2021. https://scn-portal. broadinstitute.org/.
GRIN Portal. Accessed 1 December 2021. https://grin-portal. broadinstitute.org/.
CFERV. Accessed 1 December 2021. http://functionalvariants. emory.edu/.
Touw WG, Baakman C, Black J, et al. A series of PDB-related databanks for everyday needs. Nucleic Acids Res. 2015;43:D364-8.
Laskowski RA, Chistyakov VV, Thornton JM. PDBsum more: New summaries and analyses of the known 3D structures of proteins and nucleic acids. Nucleic Acids Res. 2005;33(Suppl 1): D266-8.
Sehnal D, Svobodová Vařeková R, Berka K, et al. MOLE 2.0: Advanced approach for analysis of biomacromolecular channels. J Cheminform. 2013;5:39.
Lal D, May P, Perez-Palma E, et al. Gene family information facilitates variant interpretation and identification of disease-associated genes in neurodevelopmental disorders. Genome Med. 2020;12:28.
Lek M, Karczewski KJ, Minikel EV, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536:285-91.
Benke TA, Park K, Krey I, et al. Clinical and therapeutic significance of genetic variation in the GRIN gene family encoding NMDARs. Neuropharmacology. 2021;199:108805.
Brunklaus A, Schorge S, Smith AD, et al. SCN1A variants from bench to bedside "Improved clinical prediction from functional characterization. Human Mutat. 2020;41:363-74.
Li B, Roden DM, Capra JA, et al. The 3D mutational constraint on amino acid sites in the human proteome. Nature Communications. 2022;13:3273.
Li J, Zhang J, Tang W, et al. De novo GRIN variants in NMDA receptor M2 channel pore-forming loop are associated with neurological diseases. Human Mutat. 2019;40:2393-413.
Heyne HO, Baez-Nieto D, Iqbal S, et al. Predicting functional effects of missense variants in voltage-gated sodium and calcium channels. Sci Transl Med. 2020;12:eaay6848.
Glazer AM, Wada Y, Li B, et al. High-throughput reclassification of SCN5A variants. Am J Hum Genet. 2020;107:111-23.
Zuberi SM, Brunklaus A, Birch R, Reavey E, Duncan J, Forbes GH. Genotype-phenotype associations in SCN1A-related epilepsies. Neurology. 2011;76:594-600.
Hernandez CC, Zhang Y, Hu N, et al. GABA A receptor coupling junction and pore GABRB3 mutations are linked to early-onset epileptic encephalopathy. Sci Rep. 2017;7:15903.
Skrenkova K, Song JM, Kortus S, et al. The pathogenic S688Y mutation in the ligand-binding domain of the GluN1 subunit regulates the properties of NMDA receptors. Sci Rep. 2020;10:18576.
Endele S, Rosenberger G, Geider K, et al. Mutations in GRIN2A and GRIN2B encoding regulatory subunits of NMDA receptors cause variable neurodevelopmental phenotypes. Nat Genet. 2010;42:1021-6.
Schlegel AM, Haswell ES. Charged pore-lining residues are required for normal channel kinetics in the eukaryotic mechanosensitive ion channel MSL1. Channels (Austin). 2020;14:310-25.
Liao M, Cao E, Julius D, Cheng Y. Structure of the TRPV1 ion channel determined by electron cryo-microscopy. Nature. 2013;504:107-12.
Pan X, Li Z, Jin X, et al. Comparative structural analysis of human Nav1.1 and Nav1.5 reveals mutational hotspots for sodium channelopathies. Proc Natl Acad Sci USA. 2021;118:e2100066118.
Rao S, Klesse G, Stansfeld PJ, Tucker SJ, Sansom MSP. A heuristic derived from analysis of the ion channel structural proteome permits the rapid identification of hydrophobic gates. Proc Natl Acad Sci USA. 2019;116:13989-95.
Xenakis MN, Kapetis D, Yang Y, et al. Hydropathicity-based prediction of pain-causing NaV1.7 variants. BMC Bioinformatics. 2021;22:212.
Beckstein O, Biggin PC, Sansom MSP. A hydrophobic gating mechanism for nanopores. J Phys Chem B. 2001;105:12902-5.
Bertil H. Ionic channels of excitable membranes. 3rd edn. Sinauer; 2001.
Yazdani M, Jia Z, Chen J. Hydrophobic dewetting in gating and regulation of transmembrane protein ion channels. J Chem Phys. 2020;153:110901.
Claes L, Del-Favero J, Ceulemans B, Lagae L, Van Broeckhoven C, De Jonghe P. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am J Hum Genet. 2001;68:1327-32.
Veeramah KR, O (tm)Brien JE, Meisler MH, et al. De novo pathogenic SCN8A mutation identified by whole-genome sequencing of a family quartet affected by infantile epileptic encephalopathy and SUDEP. Am J Hum Genet. 2012;90:502-10.
Matalon D, Goldberg E, Medne L, Marsh ED. Confirming an expanded spectrum of SCN2A mutations: A case series. Epileptic Disord. 2014;16:13-8.
Hamdan FF, Gauthier J, Araki Y, et al. Excess of de novo deleterious mutations in genes associated with glutamatergic systems in nonsyndromic intellectual disability. Am J Hum Genet. 2011; 88:306-16.
Krey I, von Spiczak S, Johannesen KM, et al. L-serine treatment is associated with improvements in behavior, EEG, and seizure frequency in individuals with GRIN-related disorders due to null variants. Neurotherapeutics. 2022;19:334-41.
Soto D, Olivella M, Grau C, et al. L-Serine dietary supplementation is associated with clinical improvement of loss-of-function GRIN2B-related pediatric encephalopathy. Sci Signal. 2019;12: eaaw0936.
Pierson TM, Yuan H, Marsh ED, et al. GRIN2A mutation and early-onset epileptic encephalopathy: Personalized therapy with memantine. Ann Clin Transl Neurol. 2014;1:190-8.
Wolff M, Johannesen KM, Hedrich UBS, et al. Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders. Brain. 2017;140:1316-36.
Yoder N, Yoshioka C, Gouaux E. Gating mechanisms of acid sensing ion channels. Nature. 2018;555:397-401.
Jumper J, Richard E, Pritzel A, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596:583-9.